Description
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages.
In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report is not an update to the Drug Delivery Series, but an all new study commissioned independently to examine how new approaches are coming to market, how they are changing clinical practice, and what the potential for various technologies is in specific applications.
Table of Contents
Chapter One: Executive Summary
- Background
- Scope and Methodology
- Technology and Market Opportunities
- Polymers and Biomaterials
- Oral Drug Delivery Devices
- Pulmonary Drug Delivery
- Drug Eluting Stent Technology
- Percutaneous Drug Delivery Technology
- Ophthalmic Drug Delivery
- Colloidal Drug Delivery Technologies
- Site/Organ Specific Drug Delivery
- Needle-Free Drug Delivery Technology
Size and Growth of Market
Chapter Two: Drug Delivery Technologies
- Pharmacodynamics and Drugs for Delivery
- Small Organic Molecules
- Pharmaceutical Proteins
- Vaccines
- Genes and Antisense Drugs
- Polymers and Biomaterials
- Non-Absorbable Polymers
- Polyamine Analogs
- Magnapore Polymers
- Natural Biopolymers
- Intelligent Polymers
- Oral Drug Delivery Devices
- Extended-Release Technology
- Delayed-Release Technology
- Immediate-Dissolution Technology
- Other Progress in Oral Delivery
- Pulmonary Drug Delivery
- Notable Market Participants
- Metered Dose Inhalers
- Dry Powder Inhalers
- Nebulizers
- Drug-Eluting Stent Technology
- Percutaneous Drug Delivery Technology
- Intranasal Delivery
- Iontophoresis
- Phonophoresis
- Electroporation
- Ophthalmic Drug Delivery
- Colloidal Drug Delivery Technologies
- Site/Organ Specific Drug Delivery
Needle-Free Drug Delivery Technology
Chapter Three: Drug Delivery Applications And Markets
- Background
- Cardiovascular Diseases
- Technology Applications
- Market Assessment
- Coronary Stent Markets
- Cancer
- Technology Applications
- Market Assessment
- Central Nervous System (Cns) Applications
- Technology Applications
- Market Assessment
- Diabetes
- Technology Applications
- Market Assessment
- Fertility Control and Women’s Health
- Technology Applications
- Market Assessment
- Infectious Diseases
- Technology Applications
- Market Assessment
- Pulmonary Diseases
- Technology Applications
- Market Assessment
Chapter Four: Company Profiles
- Overview
- Abbott Laboratories
- Abbott Vascular Devices Division of Abbott Laboratories
- Alkermes, Inc.
- Andrx Corporation
- Atrix Laboratories, Inc.
- Bioject Medical Technologies
- Biovail Corporation
- Boston Scientific
- Cima Labs, Inc.
- Cordis Corporation
- Durect Corporation
- Elan Corporation
- Elite Pharmaceuticals, Inc.
- Enzon Pharmaceuticals, Inc.
- Genzyme General
- Guidant Corporation
- Guilford Pharmaceuticals, Inc.
- Jomed
- Macrochem Corporation
- Medtronic, Inc.
- Nastech Pharmaceutical Company, Inc.
- Nektar Therapeutics, Inc.
- Orapharma, Inc.
- Praecis Pharmaceuticals, Inc.
- Skyepharma Plc
- Watson Pharmaceuticals, Inc.
Chapter Five: Conclusions and Strategic Implications
- First Conclusion
- Second Conclusion
- Third Conclusion
- Fourth Conclusion
- Fifth Conclusion
- Sixth Conclusion
- Seventh Conclusion
Appendix A: Glossary of Terms and Abbreviations
Appendix B: Company Directory
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1: Estimated U.S. Market Potential for Delivery-Modified Therapeutics 2001-2010
- Figure 1-1: Distribution of the Estimated U.S. Market Potential for Delivery-Modified Therapeutics by Therapeutic Area: 2001 – 2010
CHAPTER TWO: DRUG DELIVERY TECHNOLOGIES
- Table 2-1: Key Companies Active in Drug Delivery Technology and Products
- Table 2-2: Commonly Used Polymeric Materials for Controlled Drug Release Systems
- Table 2-3: Key Companies Active in Pulmonary Drug Delivery Technology
- Table 2-4: Candidates for Drug-Eluting Stents
- Table 2-5: Companies Active in Drug-Eluting Stent Commercialization
- Table 2-6: 9-Month Restenosis Rates in Diabetic and Non-Diabetic Patients in the SIRIUS Trial
- Table 2-7: Final Results of the RAVEL Trial
- Table 2-8: Phonophoresis/Cortisol Trial Results
CHAPTER THREE: DRUG DELIVERY APPLICATIONS AND MARKETS
- Table 3-1: Estimated U.S. Market Potential for Delivery-Modified Therapeutics by Therapeutic Area, 2001 – 2010
- Figure 3-1: Distribution of the Estimated U.S. Market Potential for Delivery-Modified Therapeutics by Therapeutic Area 2001-2010
- Table 3-2: Currently Marketed Drug Delivery Modified Cardiovascular Products
- Figure 3-2: Trending in Historic and Forecast U.S. Coronary Revascularization Procedures
- Figure 3-3: Estimated Market Shares in the United States
- Table 3-3: Potential U.S. Market for Drug Delivery Modified Cardiovascular Drugs and Drug-Eluting Stents: 2001-2010 ($ Billions)
- Figure 3-4: Trending in the U.S. Market for Drug Eluting Stents: 2001-2010
- Figure 3-5: Trending in the Potential U.S. Market for Delivery Modified Cardiovascular Drugs: 2001 – 2010
- Table 3-4: Currently Marketed Drug Delivery Modified Cancer Therapy Products
- Table 3-5: Potential U.S. Market for Drug Delivery Modified Cancer Therapeutics, 2001-2010
- Figure 3-6: Trending in the Potential U.S. Market for Drug Delivery Modified Cancer Therapeutics: 2001 – 2010
- Table 3-6: Currently Marketed Drug Delivery Modified CNS Therapy Products
- Table 3-7: Potential U.S. Market for Drug Delivery Modified CNS Therapeutics 2001-2010
- Figure 3-7: Trending in the Potential U.S. Market for Delivery Modified CNS Therapeutics 2001 – 2010
- Table 3-8: Currently Marketed Drug Delivery Modified Diabetes Therapeutics 185
- Table 3-9: Potential U.S. Market for Drug Delivery Modified Diabetes Therapeutics, 2001-2010
- Figure 3-8: Trending in the Potential U.S. Market for Delivery Modified Diabetes Therapeutics 2001-2010
- Table 3-10: Currently Marketed Drug Delivery Modified Fertility and Women’s Health Products
- Table 3-11: Potential U.S. Market for Drug Delivery Modified Fertility Control and Women’s Health Drugs, 2001-2010
- Figure 3-9: Trending in the Potential U.S. Market for Delivery Modified Fertility Control and Women’s Health Drugs 2001-2010
- Table 3-12: Currently Marketed Drug Delivery Modified Infectious Disease Drugs
- Table 3-13: Potential U.S. Market for Drug Delivery Modified Infectious Disease Therapeutics, 2001-2010
- Figure 3-10: Trending in the Potential U.S. Market for Delivery Modified Infectious Disease Therapeutics: 2001 – 2010
- Table 3-14: Currently Marketed Drug Delivery Modified Pulmonary Disease Therapeutics
- Table 3-15: Potential U.S. Market for Drug Delivery Modified Pulmonary Disease Therapeutics, 2001-2010
- Figure 3-11: Trending in the Potential U.S. Market for Delivery Modified Pulmonary Disease Therapeutics: 2001 – 2010
